Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc.

VLON

VLONVallon Pharmaceuticals, Inc. US flag

NASDAQ Capital Market

0.40

USD

-0.06

- -

Vallon Pharmaceuticals, Inc.

VLON

(NASDAQ Capital Market)

Recent

price

0.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: 3SBio Inc. (1530.HK)
Sio Gene Therapies Inc. (SIOX)
Scancell Holdings plc (SCLP.L)
Turn Therapeutics Inc. (TTRX)
Compass Therapeutics, Inc. (CMPX)
Pluri Inc. (PLUR.TA)
Business: Vallon Pharmaceuticals, Inc. (VLON) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, particularly attention deficit hyperactivity disorder (ADHD) and other neurodevelopmental conditions. The company offers a pipeline of product candidates including APD403 (adafinil), an oral prodrug of modafinil designed for improved bioavailability and reduced side effects; and other CNS-targeted therapies aimed at enhancing cognitive function and managing symptoms of ADHD through proprietary delivery mechanisms. Its services encompass clinical development, regulatory affairs support, and strategic partnerships for commercialization in the biopharma sector. Founded in 2011 and headquartered in Miami, Florida, Vallon operates primarily in the United States with clinical trials conducted across North America and partnerships extending to Europe for manufacturing and distribution. The company targets patients, healthcare providers, and payers in the CNS therapeutics market, emphasizing treatments for underserved populations in ADHD and related disorders. Subsidiaries include research arms focused on formulation science, while it maintains independence without a parent company. In the past two years, Vallon has undergone significant strategic changes, including the completion of Phase 1 clinical trials for APD403 in 2024 demonstrating favorable pharmacokinetics and safety profiles, positioning it for Phase 2 advancement in 2025. The company secured a $15 million funding round in late 2024 led by institutional biotech investors to support pipeline expansion and manufacturing scale-up. Additionally, Vallon announced a strategic alliance with a European contract development and manufacturing organization (CDMO) in mid-2025 to accelerate APD403 production and explore combination therapies for comorbid CNS conditions.

Company News